Grant: Collaborative Research and Development Grants
University of Alberta
$208,892.00
Developing functional phosvitin phosphopeptides from residues after preparing phosvitin-depleted egg yolk for improved yolk stability in food applications
FY 2017-18
Summary
Our lab has been collaborating with Michael Foods through the NSERC Engage grant over the past 6 months to develop the proof-of-concept on preparing phosvitin-depleted egg yolk without deteriorating the functional property. Our industry partner is hoping that we can further mature this promising technology and scale it up from lab to pilot scale and finally to industry production at the Michael Foods plant in Winnipeg, and incorporate phosvitin-depleted egg yolk into real food applications to verify the stability during food processing and storage. The remaining granule after obtaining phosvitin-depleted egg yolk will be used for phosvitin extraction and preparing phosphopeptides that may have applications for bone and dental health. The overall objectives of the project are to develop phosvitin-depleted egg yolk with improved stability in food applications and to prepare phosvitin phosphopeptides from yolk granule with demonstrated benefits in bone and dental health. Egg processing is increasingly important in diversifying egg uses and adding value to the industry. Lipid oxidation associated with egg yolk use will not only impart the food safety and overall quality of food products, but also affect the growth and profitability of the egg industry. Therefore, the proposed research in developing phosvitin-depleted egg yolk will help the industry tackle the challenge resulting in significant benefits in improving food quality and safety as well as profitability, which contributes to a growing Canadian egg industry. The generation of co-product, phosvitin, would also allow the industry expand into new market territory as phosvitin peptides shows great potential for improving bone and dental health. For example, cost associated with osteoporosis alone in 2010 was $2.3 billion in Canada. Pharmaceutical drugs for treatment of osteoporosis are reported to increase the risk of cancer and affect the cardiovascular diseases. Therefore phosvitin peptides might provide a better long-term approach for enhancing bone and dental health products with substantial economic and social benefits to Canada.
Program
Collaborative Research and Development Grants
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
465422-2014
Name nom
Wu, Jianping
Department département
Agricultural, Food and Nutritional Science
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2014
Award amount
208892
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
100
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Agriculture and primary food production
Area of application fr
Agriculture et produits alimentaires primaires
Research subject code
6100
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food science and technology
Research subject fr
Science et technologie de l'alimentation
Partie
3
Nb partie
3
Application title
Developing functional phosvitin phosphopeptides from residues after preparing phosvitin-depleted egg yolk for improved yolk stability in food applications
Keyword
NSERC
Application summary
Our lab has been collaborating with Michael Foods through the NSERC Engage grant over the past 6 months to develop the proof-of-concept on preparing phosvitin-depleted egg yolk without deteriorating the functional property. Our industry partner is hoping that we can further mature this promising technology and scale it up from lab to pilot scale and finally to industry production at the Michael Foods plant in Winnipeg, and incorporate phosvitin-depleted egg yolk into real food applications to verify the stability during food processing and storage. The remaining granule after obtaining phosvitin-depleted egg yolk will be used for phosvitin extraction and preparing phosphopeptides that may have applications for bone and dental health. The overall objectives of the project are to develop phosvitin-depleted egg yolk with improved stability in food applications and to prepare phosvitin phosphopeptides from yolk granule with demonstrated benefits in bone and dental health. Egg processing is increasingly important in diversifying egg uses and adding value to the industry. Lipid oxidation associated with egg yolk use will not only impart the food safety and overall quality of food products, but also affect the growth and profitability of the egg industry. Therefore, the proposed research in developing phosvitin-depleted egg yolk will help the industry tackle the challenge resulting in significant benefits in improving food quality and safety as well as profitability, which contributes to a growing Canadian egg industry. The generation of co-product, phosvitin, would also allow the industry expand into new market territory as phosvitin peptides shows great potential for improving bone and dental health. For example, cost associated with osteoporosis alone in 2010 was $2.3 billion in Canada. Pharmaceutical drugs for treatment of osteoporosis are reported to increase the risk of cancer and affect the cardiovascular diseases. Therefore phosvitin peptides might provide a better long-term approach for enhancing bone and dental health products with substantial economic and social benefits to Canada.